Current applications of multiparameter flow cytometry in plasma
cell disorders

J 2017

Current applications of multiparameter flow cytometry in plasma cell disorders

JELÍNEK, Tomáš; Renata BEZDĚKOVÁ; M ZÁTOPKOVÁ; L BURGOS; M SIMICEK et al.

Základní údaje

Originální název

Current applications of multiparameter flow cytometry in plasma cell disorders

Autoři

JELÍNEK, Tomáš; Renata BEZDĚKOVÁ; M ZÁTOPKOVÁ; L BURGOS; M SIMICEK; T SEVCIKOVA; B PAIVA a Roman HÁJEK

Vydání

Blood Cancer Journal, LONDON, NATURE PUBLISHING GROUP, 2017, 2044-5385

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 8.125

Označené pro přenos do RIV

DOI

https://doi.org/10.1038/bcj.2017.90

UT WoS

000413469800001

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 6. 2. 2019 11:56, Mgr. Renata Bezděková, Ph.D.

Anotace

V originále

Multiparameter flow cytometry (MFC) has become standard in the management of patients with plasma cell (PC) dyscrasias, and could be considered mandatory in specific areas of routine clinical practice. It plays a significant role during the differential diagnostic workup because of its fast and conclusive readout of PC clonality, and simultaneously provides prognostic information in most monoclonal gammopathies. Recent advances in the treatment and outcomes of multiple myeloma led to the implementation of new response criteria, including minimal residual disease (MRD) status as one of the most relevant clinical endpoints with the potential to act as surrogate for survival. Recent technical progress led to the development of next-generation flow (NGF) cytometry that represents a validated, highly sensitive, cost-effective and widely available technique for standardized MRD evaluation, which also could be used for the detection of circulating tumor cells. Here we review current applications of MFC and NGF in most PC disorders including the less frequent solitary plasmocytoma, light-chain amyloidosis or Waldenstrom macroglobulinemia.

Citovat

JELÍNEK, Tomáš; Renata BEZDĚKOVÁ; M ZÁTOPKOVÁ; L BURGOS; M SIMICEK; T SEVCIKOVA; B PAIVA a Roman HÁJEK. Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer Journal. LONDON: NATURE PUBLISHING GROUP, 2017, roč. 7, 12 s. ISSN 2044-5385. Dostupné z: https://doi.org/10.1038/bcj.2017.90.

@article{1408688,
   author = {Jelínek, Tomáš and Bezděková, Renata and Zátopková, M and Burgos, L and Simicek, M and Sevcikova, T and Paiva, B and Hájek, Roman},
   article_location = {LONDON},
   doi = {https://doi.org/10.1038/bcj.2017.90},
   language = {eng},
   issn = {2044-5385},
   journal = {Blood Cancer Journal},
   title = {Current applications of multiparameter flow cytometry in plasma cell disorders},
   url = {http://dx.doi.org/10.1038/bcj.2017.90},
   volume = {7},
   year = {2017}
}

TY  - JOUR
ID  - 1408688
AU  - Jelínek, Tomáš - Bezděková, Renata - Zátopková, M - Burgos, L - Simicek, M - Sevcikova, T - Paiva, B - Hájek, Roman
PY  - 2017
TI  - Current applications of multiparameter flow cytometry in plasma cell disorders
JF  - Blood Cancer Journal
VL  - 7
PB  - NATURE PUBLISHING GROUP
SN  - 20445385
UR  - http://dx.doi.org/10.1038/bcj.2017.90
L2  - http://dx.doi.org/10.1038/bcj.2017.90
N2  - Multiparameter flow cytometry (MFC) has become standard in the management of patients with plasma cell (PC) dyscrasias, and could be considered mandatory in specific areas of routine clinical practice. It plays a significant role during the differential diagnostic workup because of its fast and conclusive readout of PC clonality, and simultaneously provides prognostic information in most monoclonal gammopathies. Recent advances in the treatment and outcomes of multiple myeloma led to the implementation of new response criteria, including minimal residual disease (MRD) status as one of the most relevant clinical endpoints with the potential to act as surrogate for survival. Recent technical progress led to the development of next-generation flow (NGF) cytometry that represents a validated, highly sensitive, cost-effective and widely available technique for standardized MRD evaluation, which also could be used for the detection of circulating tumor cells. Here we review current applications of MFC and NGF in most PC disorders including the less frequent solitary plasmocytoma, light-chain amyloidosis or Waldenstrom macroglobulinemia.
ER  -

JELÍNEK, Tomáš; Renata BEZDĚKOVÁ; M ZÁTOPKOVÁ; L BURGOS; M SIMICEK; T SEVCIKOVA; B PAIVA a Roman HÁJEK. Current applications of multiparameter flow cytometry in plasma cell disorders. \textit{Blood Cancer Journal}. LONDON: NATURE PUBLISHING GROUP, 2017, roč.~7, 12 s. ISSN~2044-5385. Dostupné z: https://doi.org/10.1038/bcj.2017.90.

Přehled o publikaci